Table 3.
Serum and urinary concentrations of biomarkers at baseline and day 7, with change from baseline after 7 days of treatment with dapagliflozin vs placebo
| Treatment Period | sUA (µmol/L) | Peak uUA excretion (mg) | Creatinine (µmol/L) | Cystatin C (mg/L) | Blood Urea Nitrogen (mmol/L) | Sodium (mmol/L) | Potassium (mmol/L) |
|---|---|---|---|---|---|---|---|
| Baseline, mean (SD) | |||||||
| Dapagliflozin period | 430.1 (65.0) | 47.3 (13.0) | 94.4 (14.2) | 1.0 (0.2) | 5.2 (1.3) | 139 (3.0) | 4.3 (0.3) |
| Placebo period | 398.7 (53.3) | 52.2 (18.5) | 95.5 (14.4) | 0.9 (0.2) | 5.1 (1.9) | 139 (3.0) | 4.3 (0.3) |
| Day 7, mean (SD) | |||||||
| Dapagliflozin period | 103.5 (39.6) | 34.6 (13.0) | 91.9 (12.3) | 1.0 (0.2) | 4.9 (0.9) | 139 (2.0) | 4.1 (0.3) |
| Placebo period | 133.8 (57.5) | 39.3 (20.4) | 90.5 (11.8) | 1.0 (0.1) | 4.7 (0.9) | 139 (2.0) | 4.2 (0.3) |
| Change from baseline, LSM (95% CI) | |||||||
| Dapagliflozin period | −327.16 (−352.56 to –301.76) | −12.87 (−21.03 to −4.70) | −2.511 (−5.809 to 0.787) | 0.022 (−0.006to 0.051) | −0.268 (−0.740 to 0.205) | 0.720 (−0.245 to 1.686) | −0.146 (−0.261to –0.031) |
| Placebo period | −264.85 (−290.06 to −239.64) | −13.15 (−21.31 to −4.98) | −5.034 (−8.294 to −1.774) | 0.020 (−0.008 to 0.048) | −0.397 (−0.862 to 0.069) | −0.028 (−0.979 to 0.923) | −0.114 (−0.227 to −0.001) |
| Mean difference (95% CI) | −62.31 (−82.84to −41.78) | 0.28 (−8.67 to 9.22) | 2.523 (−0.935 to 5.981) | 0.003 (−0.037 to 0.043) | 0.129 (−0.539 to 0.797) | 0.748 (−0.535 to 2.031) | −0.032 (−0.194 to 0.129) |
Abbreviations: CI, confidence interval; LSM, least squares mean; SD, standard deviation; sUA, serum uric acid; uUA, urinary uric acid.